Tammas Kelly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tammas Kelly has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Z. Lieberman
Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
4 shared publications Lawrence Denmark
The Depression & Bipolar Clinic of Colorado, 400 East Horsetooth Road, Suite 300, Fort Collins, CO 80525, United States(2)
2 shared publicationsGinger Brasuell
1 shared publicationLanny Douglas
1 shared publication
Latest Publications
- 9 February 2019
- Published by Wiley in Bipolar Disorders
- Vol. 21 (4) , 302-308
Lithium and the Woozle effect
Objectives: Lithium is the oldest and most‐studied treatment for bipolar depression. Many treatment guidelines place lithium as a top treatment recommendation for bipolar depression; yet some guidelines do not recommend lithium at all. These discrepancies were explored by examining the following errors: the Woozle effect (evidence by citation), reference inflation (overreporting the findings of cited studies) and belief perseverance (maintaining a belief despite new contradictory evidence) as possible causes for these discrepancies.Methods: Various search engines were used to find treatment guidelines for bipolar depression. The references cited in these guidelines were examined and analyzed in‐depth.Results: Ten guidelines recommend lithium as a first‐line treatment for bipolar depression. Five did not recommend lithium at all for the treatment of bipolar depression. These discrepancies are remarkable. The references cited in the treatment guidelines were examined and do not favor lithium as a treatment for bipolar depression. The guidelines that favored lithium for the treatment of bipolar depression suffered numerous Woozle effects, reference inflation and belief perseverance are prevalent in guidelines that recommend lithium as a first‐line treatment. All three errors are principally slippery slopes. These errors do not involve a deliberate attempt to mislead and may reflect failures of the peer review process.Conclusions: These errors may be common, as demonstrated in the case of lithium, interfering with our understanding and practice of evidence‐based medicine. Both authors and journals need to guard against these types of errors in order to achieve sound evidence‐based medical practices.
- 9 February 2019
- Published by Wiley in Bipolar Disorders
- Vol. 21 (4) , 302-308
Lithium and the Woozle effect
Objectives: Lithium is the oldest and most‐studied treatment for bipolar depression. Many treatment guidelines place lithium as a top treatment recommendation for bipolar depression; yet some guidelines do not recommend lithium at all. These discrepancies were explored by examining the following errors: the Woozle effect (evidence by citation), reference inflation (overreporting the findings of cited studies) and belief perseverance (maintaining a belief despite new contradictory evidence) as possible causes for these discrepancies.Methods: Various search engines were used to find treatment guidelines for bipolar depression. The references cited in these guidelines were examined and analyzed in‐depth.Results: Ten guidelines recommend lithium as a first‐line treatment for bipolar depression. Five did not recommend lithium at all for the treatment of bipolar depression. These discrepancies are remarkable. The references cited in the treatment guidelines were examined and do not favor lithium as a treatment for bipolar depression. The guidelines that favored lithium for the treatment of bipolar depression suffered numerous Woozle effects, reference inflation and belief perseverance are prevalent in guidelines that recommend lithium as a first‐line treatment. All three errors are principally slippery slopes. These errors do not involve a deliberate attempt to mislead and may reflect failures of the peer review process.Conclusions: These errors may be common, as demonstrated in the case of lithium, interfering with our understanding and practice of evidence‐based medicine. Both authors and journals need to guard against these types of errors in order to achieve sound evidence‐based medical practices.
- 14 June 2018
- Published by Wiley in International Journal of Methods in Psychiatric Research
- Vol. 27 (3) , e1725
Prospective: Is bipolar disorder being overdiagnosed?
Objectives: Many studies indicate that bipolar disorders are underdiagnosed. Yet from 2007 to 2008, a series of publications asserted that bipolar disorders were being overdiagnosed. This review examines the methods used in the studies that reported bipolar disorders were being overdiagnosed.Methods: A literature search for studies with original data related to overdiagnosis of bipolar disorders was performed.Results: Four studies were found indicating bipolar disorders were being overdiagnosed. The Structured Clinical Interview of the Diagnostic and Statistical Manual of Mental Disorders (SCID) was used in the diagnostic process. The studies compared the clinical diagnosis of bipolar disorder to a single SCID interview without interviewing family or reviewing old records. The studies assumed the SCID diagnosis was correct.Conclusions: Numerous concerns were found. The SCID frequently missed diagnosis of bipolar, the definitions of bipolar disorder are so narrow and conservative that the outcomes of the studies may have been predetermined. Ultimately, the studies compared the strength of a diagnosis made by a treating psychiatrist to a SCID diagnosis collected with virtually no information from the clinician. The assumption that the SCID diagnosis is always correct and the clinician is always wrong is unsupportable. The premise that bipolar disorders are being overdiagnosed is unsupported by reasonable science.
- 14 June 2018
- Published by Wiley in International Journal of Methods in Psychiatric Research
- Vol. 27 (3) , e1725
Prospective: Is bipolar disorder being overdiagnosed?
Objectives: Many studies indicate that bipolar disorders are underdiagnosed. Yet from 2007 to 2008, a series of publications asserted that bipolar disorders were being overdiagnosed. This review examines the methods used in the studies that reported bipolar disorders were being overdiagnosed.Methods: A literature search for studies with original data related to overdiagnosis of bipolar disorders was performed.Results: Four studies were found indicating bipolar disorders were being overdiagnosed. The Structured Clinical Interview of the Diagnostic and Statistical Manual of Mental Disorders (SCID) was used in the diagnostic process. The studies compared the clinical diagnosis of bipolar disorder to a single SCID interview without interviewing family or reviewing old records. The studies assumed the SCID diagnosis was correct.Conclusions: Numerous concerns were found. The SCID frequently missed diagnosis of bipolar, the definitions of bipolar disorder are so narrow and conservative that the outcomes of the studies may have been predetermined. Ultimately, the studies compared the strength of a diagnosis made by a treating psychiatrist to a SCID diagnosis collected with virtually no information from the clinician. The assumption that the SCID diagnosis is always correct and the clinician is always wrong is unsupportable. The premise that bipolar disorders are being overdiagnosed is unsupported by reasonable science.
- 1 February 2017
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 37 (1) , 99-101
The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression
Background: Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical experience has suggested that doses beyond 5 mg are rarely efficacious. Methods: Data were gathered from patients with bipolar II or bipolar not otherwise specified depression using a retrospective chart review. Efficacy was assessed with the Clinical Global Impression-Improvement score. Patients who had at least 2 trials of aripiprazole were included in a retrospective off-on-off-on experimental design. All patients were on other medications when aripiprazole was started. Patients were treated with doses of 1 to 5 mg. Findings: On average, patients were rated improved or very much improved compared with baseline. Sixteen of 211 patients worsened or experienced no change. Forty-four patients (21%) discontinued due to adverse effects. The group of patients who underwent off-on-off-on trials experienced statistically significant improvement when they started and restarted aripiprazole, and statistically significant worsening when they discontinued it. Conclusions: When treating bipolar II or bipolar not otherwise specified depression, low doses of aripiprazole, 5 mg or less, may be more effective and better tolerated than higher ones. Clinicians should start treatment with a very low dose and give patients time to respond.
- 1 February 2017
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 37 (1) , 99-101
The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression
Background: Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical experience has suggested that doses beyond 5 mg are rarely efficacious. Methods: Data were gathered from patients with bipolar II or bipolar not otherwise specified depression using a retrospective chart review. Efficacy was assessed with the Clinical Global Impression-Improvement score. Patients who had at least 2 trials of aripiprazole were included in a retrospective off-on-off-on experimental design. All patients were on other medications when aripiprazole was started. Patients were treated with doses of 1 to 5 mg. Findings: On average, patients were rated improved or very much improved compared with baseline. Sixteen of 211 patients worsened or experienced no change. Forty-four patients (21%) discontinued due to adverse effects. The group of patients who underwent off-on-off-on trials experienced statistically significant improvement when they started and restarted aripiprazole, and statistically significant worsening when they discontinued it. Conclusions: When treating bipolar II or bipolar not otherwise specified depression, low doses of aripiprazole, 5 mg or less, may be more effective and better tolerated than higher ones. Clinicians should start treatment with a very low dose and give patients time to respond.
- 1 December 2016
- Published by Elsevier in Medical Hypotheses
- Vol. 97, 16-21
A hypothesis on the mechanism of action of high-dose thyroid in refractory mood disorders
- 1 December 2016
- Published by Elsevier in Medical Hypotheses
- Vol. 97, 16-21
A hypothesis on the mechanism of action of high-dose thyroid in refractory mood disorders
- 1 November 2016
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 71, 1-6
Elevated levels of circulating thyroid hormone do not cause the medical sequelae of hyperthyroidism
- 1 November 2016
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 71, 1-6
Elevated levels of circulating thyroid hormone do not cause the medical sequelae of hyperthyroidism
- 1 May 2015
- Published by Elsevier in Journal of Affective Disorders
- Vol. 177, 49-58
An examination of myth: A favorable cardiovascular risk-benefit analysis of high-dose thyroid for affective disorders
- 1 May 2015
- Published by Elsevier in Journal of Affective Disorders
- Vol. 177, 49-58
An examination of myth: A favorable cardiovascular risk-benefit analysis of high-dose thyroid for affective disorders
- 1 October 2014
- Published by Elsevier in Journal of Affective Disorders
- Vol. 167, 333-335
The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS
- 1 October 2014
- Published by Elsevier in Journal of Affective Disorders
- Vol. 167, 333-335
The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS
- 1 September 2014
- Published by Elsevier in Journal of Affective Disorders
- Vol. 166, 353-358
A favorable risk-benefit analysis of high dose thyroid for treatment of bipolar disorders with regard to osteoporosis
- 1 September 2014
- Published by Elsevier in Journal of Affective Disorders
- Vol. 166, 353-358
A favorable risk-benefit analysis of high dose thyroid for treatment of bipolar disorders with regard to osteoporosis
- 1 October 2013
- Published by Elsevier in Journal of Affective Disorders
- Vol. 151 (1) , 54-58
The high prevalence of obstructive sleep apnea among patients with bipolar disorders
- 1 October 2013
- Published by Elsevier in Journal of Affective Disorders
- Vol. 151 (1) , 54-58
The high prevalence of obstructive sleep apnea among patients with bipolar disorders
- Open Access
- 9 January 2009
- Published by Wiley in Bipolar Disorders
- Vol. 11 (1) , 107-108
Letter to the Editor regarding: ‘Is bipolar disorder overdiagnosed among patients with substance abuse?’
- 9 January 2009
- Published by Wiley in Bipolar Disorders
- Vol. 11 (1) , 107-108
Open AccessLetter to the Editor regarding: ‘Is bipolar disorder overdiagnosed among patients with substance abuse?’